Monitoring and improving treatment for non-Hodgkin lymphoma patients in the Czech Republic

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Czech National Lymphoma Registry (NiHiL) aims to collect and analyze epidemiological data to enhance the diagnostic evaluation and treatment quality for patients with non-Hodgkin lymphoma (NHL). Patients are registered anonymously at diagnosis, and their data is updated throughout treatment and follow-up. The registry includes comprehensive information on lymphoma subtypes, treatment responses, and long-term outcomes, allowing for detailed analysis of survival rates and treatment efficacy. This initiative encompasses approximately 75% of NHL patients in the Czech Republic, providing a robust dataset for improving patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* lymphoma diagnosis
* treated in the Czech Republic
* signed informed consent

Exclusion Criteria:

* unsigned informed consent
* age \<18 y

Where it's running

• Charles University General Hospital
  Prague, Czechia Recruiting

Study contacts

• Principal investigator: Marek Trneny, prof. MD — Charles University General Hospital, Prague, CZ
• Study coordinator: Marek Trneny, prof. MD
• Email: trneny@cesnet.cz
• Phone: +420224962061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ALA-101 in CD19+ blood cancers

  A small early-phase test to see if ALA-101, an off-the-shelf CAR-iNKT cell therapy, is safe and potentially effective in adults with CD19-positive NHL or leukemia.

  Recruiting Phase 1 Arovella Therapeutics Ltd · Sydney, New South Wales and 4 other locations · NCT07518329

• Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

  This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07478848

• LV009 infusion for relapsed/refractory CD19-positive blood cancers

  This early-phase study will test whether LV009 infusion is safe and how it behaves in adults with relapsed or refractory CD19-positive blood cancers such as NHL or ALL.

  Recruiting Early Phase 1 PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Hefei, Anhui · NCT07312630

• Poseltinib (NB02) alone for relapsed or refractory non-Hodgkin lymphoma

  This trial tests oral poseltinib (NB02) to see if it is safe and shows anti-lymphoma activity in adults 19–80 with relapsed or refractory follicular, mantle cell, or marginal zone lymphoma after at least two prior treatments.

  Recruiting at 6 sites Phase 1 NOBO Medicine · Hwasun and 5 other locations · NCT07114367

• OriV508 injection for relapsed or refractory multiple myeloma and aggressive B‑cell lymphoma

  We will try OriV508, an in‑body lentiviral therapy carrying a BCMA/CD19 dual‑target CAR, in adults whose multiple myeloma or aggressive B‑cell lymphoma has returned or not responded to prior treatments.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07101705

• CAR-T cell therapy for patients with relapsed B cell cancers

  This study is testing a new CAR-T cell therapy for adults with relapsed B cell cancers to see how well it works and if different manufacturing methods make a difference in treatment outcomes.

  Recruiting Phase 1/2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT04186520

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.